TY - JOUR
T1 - Circulating tumor DNA in non-small-cell lung cancer
T2 - A primer for the clinician
AU - Singh, Aditi P.
AU - Cheng, Haiying
AU - Guo, Xiaoling
AU - Levy, Benjamin
AU - Halmos, Balazs
N1 - Publisher Copyright:
© 2018 American Society of Clinical Oncology.
PY - 2017
Y1 - 2017
N2 - Circulating tumor DNA (ctDNA) consists of short, double-stranded DNA fragments that are released into the circulation by tumor cells. With the advent of newer molecular platforms, ctDNA can be detected with high sensitivity and specificity in plasma. The assay's noninvasive nature, ability to reflect intratumoral heterogeneity, short turnaround time, and ability to obtain serial samples make it an attractive option compared with traditional tissue biopsy tumor sequencing. Currently, this technology is mostly being used for the detection of EGFR mutations in patients with advanced non-small-cell lung cancer where tissue is inadequate to detect EGFR mutations that drive acquired resistance,mostnotablyEGFRT790M.Emerginguses include the incorporation of ctDNA testing into primary diagnosis, treatment monitoring, detection of minimal residual disease, and detection of early-stage disease in screening populations. This review summarizes both validated and evolving uses of ctDNA testing in non-small-cell lung cancer in the context of oncologists' daily practice and some of its potential challenges in the era of targeted therapy and immunotherapy.
AB - Circulating tumor DNA (ctDNA) consists of short, double-stranded DNA fragments that are released into the circulation by tumor cells. With the advent of newer molecular platforms, ctDNA can be detected with high sensitivity and specificity in plasma. The assay's noninvasive nature, ability to reflect intratumoral heterogeneity, short turnaround time, and ability to obtain serial samples make it an attractive option compared with traditional tissue biopsy tumor sequencing. Currently, this technology is mostly being used for the detection of EGFR mutations in patients with advanced non-small-cell lung cancer where tissue is inadequate to detect EGFR mutations that drive acquired resistance,mostnotablyEGFRT790M.Emerginguses include the incorporation of ctDNA testing into primary diagnosis, treatment monitoring, detection of minimal residual disease, and detection of early-stage disease in screening populations. This review summarizes both validated and evolving uses of ctDNA testing in non-small-cell lung cancer in the context of oncologists' daily practice and some of its potential challenges in the era of targeted therapy and immunotherapy.
UR - http://www.scopus.com/inward/record.url?scp=85042439539&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85042439539&partnerID=8YFLogxK
U2 - 10.1200/PO.17.00054
DO - 10.1200/PO.17.00054
M3 - Review article
AN - SCOPUS:85042439539
SN - 2473-4284
VL - 2017
SP - 1
EP - 13
JO - JCO Precision Oncology
JF - JCO Precision Oncology
IS - 1
ER -